Autonomix medical, inc. to highlight technology and early proof-of-concept study results in a poster presentation at the 2025 european conference on interventional oncology (ecio)

The woodlands, tx, april 03, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 european conference on interventional oncology (ecio), being held april 13-16, 2025 in rotterdam, netherlands.
AMIX Ratings Summary
AMIX Quant Ranking